Maísa Veríssimo

1 Introduction Historically, people with haemophilia (PwH) were advised against physical activity (PA) due to concerns about bleeding risks [1]. However, the advent of clotting factor replacement therapy and the shift towards prophylactic treatment regimens, consisting of regular administration of therapeutic products to maintain haemostasis and prevent acute haemorrhagic episodes, have changed this paradigm.